Medidata Rave Omics Collaboration Uncovers Novel Insights for Rare Disease Research
December 04 2018 - 8:30AM
Business Wire
Discovery of biomarker evidence in Castleman
Disease exemplifies the value of personalized medicine in rare
diseases
- The Castleman Disease Collaborative
Network presented new research supported by Medidata at 60th Annual
Meeting of the American Society of Hematology
- Application of Medidata Rave Omics
reveals new patient subgroups that can accelerate diagnosis and
treatment
- Medidata data analysis in collaboration
with the Castleman Disease Collaborative Network advances
personalized medicine for life-threatening disorder
The Castleman Disease Collaborative Network (CDCN) discovered
new patient subgroups, based on previously unknown proteomic
signatures, with Medidata’s Rave Omics, a machine learning-based
solution. These discoveries provide novel insights into treatment
response and potential new drug targets, highlighting the value of
precision medicine.
Medidata (NASDAQ:MDSO) and the CDCN presented these insights at
the 60th Annual Meeting of the American Society of Hematology
(ASH).
Idiopathic Multicentric Castleman Disease (iMCD) is a rare,
difficult to diagnose, life-threatening disorder.1 The CDCN
advances research programs to develop better diagnostic methods,
identify patients that will respond to approved therapy and find
new drug targets to develop new therapies.
“iMCD stumped my doctors, and they didn’t think I would survive.
My mission today is to bring new treatment options and hope to
Castleman Disease patients and other poorly understood rare
diseases,” said Dr. David Fajgenbaum, co-founder and executive
director of the Castleman Disease Collaborative Network. “Rare
diseases often lack sufficient sample sizes and necessary resources
to make critical discoveries, which has limited the development of
new treatment options for patients. This collaborative study
combined patient samples from around the world and the Rave Omics
tool to overcome these challenges and help to better understand
this disease. We are now working together to use this data to
personalize treatment for Castleman disease.”
Medidata Rave Omics enabled the discovery of novel biomarkers
for Castleman disease. With unparalleled industry expertise,
Medidata data scientists collaborated with the Castleman Disease
Collaborative Network to make the following insights:
- Six new patient subsets reflecting
either distinct subtypes or proteomic disease states
- Evidence of proteomic predictors of
anti-interleukin-6 treatment response
- Etiological insights into the poorly
understood rare disease and toward new potential drug targets
“Medidata's analytics empower researchers to make new
discoveries for all patients, including those with rare diseases,”
said Glen de Vries, co-founder and president, Medidata. “We’re
proud to help make personalized medicine and the development of
targeted treatments possible with Rave Omics.”
Medidata Rave Omics streamlines omic data capture, linking and
analysis inside the clinical study process. To learn more about
Medidata, visit mdsol.com.
1 Fajgenbaum D, Ruth J, Kelleher D, Rubenstein A. Lancet
Haematology. 2016;3:150-152
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
About Castleman Disease Collaborative Network (CDCN)
CDCN is a global initiative dedicated to accelerating research
and treatment for Castleman disease (CD) to improve survival for
all patients with CD. The CDCN’s innovative approach first involved
building a global community of over 400 physicians and researchers,
assembling a scientific advisory board of 28 experts from eight
countries, and supporting and engaging patients in research
prioritization. Then, the CDCN crowdsourced among the global
community to identify gaps in medical knowledge and determine high
priority research projects. In parallel, the CDCN connects and
supports thousands of CD patients around the world. Now, the CDCN
recruits top researchers to conduct studies, and works with
patients, loved ones, and the public to raise funding to enable
these studies. More information is available at: www.CDCN.org
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181204005278/en/
Medidata:Investors:Betsy Frank, +1
917-522-4620bfrank@mdsol.com
Media:Erik Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024